Patents Assigned to Aelan Cell Technologies, Inc.
  • Patent number: 12210018
    Abstract: Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: January 28, 2025
    Assignee: AELAN CELL TECHNOLOGIES, INC.
    Inventors: Victoria Lunyak, James Robert Tollervey
  • Patent number: 12138282
    Abstract: Described herein are companion methods and kits useful for IL-2-based therapies and for mesenchymal stem cell-based therapies.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: November 12, 2024
    Assignee: AELAN CELL TECHNOLOGIES, INC.
    Inventors: Victoria Lunyak, Meenakshi Gaur
  • Patent number: 11505621
    Abstract: Provided herein are antibodies that specifically bind a protein comprising an H1.0K180me2 antigen or a peptide thereof, methods of making such antibodies, and methods of using such antibodies for therapeutics and diagnostics.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: November 22, 2022
    Assignee: AELAN CELL TECHNOLOGIES, INC.
    Inventors: Victoria V. Lunyak, James Robert Tollervey
  • Patent number: 11293065
    Abstract: Provided herein are methods and compositions for assessing the quality and potential of stem cells in a sample. Such methods and compositions are useful for helping to ensure the safety and quality of a population of stem cells before it is used in a subject.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: April 5, 2022
    Assignee: AELAN CELL TECHNOLOGIES, INC.
    Inventors: Victoria Lunyak, Meenakshi Gaur
  • Patent number: 11291689
    Abstract: Provided herein are methods and devices related to inducing a population of self-renewing or senescent stem cells, to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Also provided are compositions and methods for inducing senescence, useful for inducing senescence in a population of stem cells, in order to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Methods and devices to control and customize the production of the beneficial factors for the requirements of a disease or disorder being treated are described. Also provided are factor production units for the production of the beneficial factors, and devices for the delivery of the beneficial factors to an individual in need.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: April 5, 2022
    Assignee: AELAN CELL TECHNOLOGIES, INC.
    Inventors: Victoria Lunyak, Meenakshi Gaur
  • Patent number: 10921324
    Abstract: Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 16, 2021
    Assignee: AELAN CELL TECHNOLOGIES, INC.
    Inventors: Victoria Lunyak, James Robert Tollervey
  • Publication number: 20200362056
    Abstract: Provided herein are antibodies that specifically bind a protein comprising an H1.0K180me2 antigen or a peptide thereof, methods of making such antibodies, and methods of using such antibodies for therapeutics and diagnostics.
    Type: Application
    Filed: April 23, 2020
    Publication date: November 19, 2020
    Applicants: Aelan Cell Technologies, Inc., Aelan Cell Technologies, Inc.
    Inventors: Victoria V. LUNYAK, James Robert TOLLERVEY